ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,142.00
-0.13%
S&P ASX All Technology
3,417.00
0.40%
Brent Oil
74.545
1.10%
US Dollar vs AUD
1.45276
-0.72%
Bitcoin
63,718.38
0.62%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Merck and Co Inc (MRK)

  7. Merck and Co Inc (MRK) News

MRK

Merck (MRK)

Merck and Co Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:MRK
DateTimeSourceHeadlineSymbolCompany
24/09/202422:06Business WireMerck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia VirusNYSE:MRKMerck and Co Inc
20/09/202421:30Business WireMerck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic CancersNYSE:MRKMerck and Co Inc
18/09/202420:45Business WireFDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)NYSE:MRKMerck and Co Inc
17/09/202420:00Business WirePatritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 TrialNYSE:MRKMerck and Co Inc
16/09/202421:00GlobeNewswire Inc.BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024NYSE:MRKMerck and Co Inc
16/09/202400:30Business WireKEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)NYSE:MRKMerck and Co Inc
15/09/202422:45Business WireTen-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced MelanomaNYSE:MRKMerck and Co Inc
15/09/202400:35Business WireKEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular CarcinomaNYSE:MRKMerck and Co Inc
15/09/202400:30Business WireMerck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical CancerNYSE:MRKMerck and Co Inc
14/09/202417:15Business WireKEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ AdenocarcinomaNYSE:MRKMerck and Co Inc
12/09/202421:00PR Newswire (Canada)Santé Canada approuve KEYTRUDA® pour le traitement, en monothérapie, des adultes et des enfants atteints d'une tumeur solide non résécable ou métastatique associée à une forte instabilité microsatellitaire (IMS) ou à une déficience du système dNYSE:MRKMerck and Co Inc
12/09/202421:00PR Newswire (Canada)Health Canada Approves KEYTRUDA® as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prioNYSE:MRKMerck and Co Inc
11/09/202420:45Business WireMerck to Participate in the Bank of America 2024 Global Healthcare ConferenceNYSE:MRKMerck and Co Inc
11/09/202420:30Business WireMerck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese MalesNYSE:MRKMerck and Co Inc
11/09/202408:53AllPennyStocks.comJunior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving LivesNYSE:MRKMerck and Co Inc
08/09/202401:30Business WireIfinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 TrialNYSE:MRKMerck and Co Inc
05/09/202421:00PR Newswire (Canada)Merck Canada et l'Alliance pharmaceutique pancanadienne (APP) concluent avec succès les négociations relatives à WELIREG® (belzutifan)NYSE:MRKMerck and Co Inc
05/09/202421:00PR Newswire (Canada)Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WELIREG® (belzutifan)NYSE:MRKMerck and Co Inc
05/09/202405:00PR Newswire (Canada)WINREVAIR® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial HypertensionNYSE:MRKMerck and Co Inc
05/09/202405:00PR Newswire (Canada)L'utilisation de WINREVAIR® (sotatercept) est maintenant autorisée au Canada pour les adultes atteints d'hypertension artérielle pulmonaireNYSE:MRKMerck and Co Inc
04/09/202420:45Business WireMerck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024NYSE:MRKMerck and Co Inc
04/09/202420:40Business WireMerck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular EdemaNYSE:MRKMerck and Co Inc
03/09/202420:45Business WireEuropean Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in AdultsNYSE:MRKMerck and Co Inc
29/08/202420:45Business WireMerck to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNYSE:MRKMerck and Co Inc
29/08/202420:30Business WireMerck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 TrialsNYSE:MRKMerck and Co Inc
27/08/202420:45Business WireMerck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential ThrombocythemiaNYSE:MRKMerck and Co Inc
26/08/202420:45Business WireMerck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-IIINYSE:MRKMerck and Co Inc
22/08/202421:00PR Newswire (Canada)Health Canada Approves KEYTRUDA® for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC, in combination with enfortumab vedotinNYSE:MRKMerck and Co Inc
22/08/202421:00PR Newswire (Canada)Santé Canada approuve KEYTRUDA® en association avec l'enfortumab védotine pour le traitement des patients adultes atteints d'un cancer urothélial non résécable localement avancé ou métastatique n'ayant jamais reçu de traitement à action généralNYSE:MRKMerck and Co Inc
09/08/202420:45Business WireMerck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon BiopharmaceuticalNYSE:MRKMerck and Co Inc
 Showing the most relevant articles for your search:NYSE:MRK

Your Recent History

EU
HAGG
Hsbc Bloomberg Global Su...
TSXV
SEB
Smart Employee Benefits
USOTC
LTSAP
Osaic Financial Services (CE)
USOTC
PURE
PURE Bioscience (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved